Triple therapy regime puts patients with leukemic form of cutaneous lymphoma in remission

A three-pronged immunotherapy approach nearly doubles five-year survival among patients with rare leukemic form of cutaneous T-cell lymphoma, according to a new study by dermatologists from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania, USA.

In a retrospective study of 98 patients with advanced Sezary Syndrome – treated over a 25 year time span at the Hospital of the University of Pennsylvania – patients treated with combination therapy experienced a higher overall response rate compared to previous studies (74.4% versus 63%), and a higher complete response rate (30% vs 20%). The five-year overall survival rate was also higher than previously reported (55% vs 30%). Researchers concluded that combination immunotherapy is more effective than a single treatment.

"This rare disease, if caught soon enough, may no longer be fatal, thanks to advances in treatment and our understanding of the disease," said Alain Rook, professor of dermatology and senior author of the study, which appears on-line in the Archives of Dermatology, a JAMA/Archives journal. "In addition, our improved understanding of prognostic factors will help us tailor treatments for each patient, based on the aggressiveness of their disease, and better predict individual patient outcomes," he noted.